抗菌膏 | 92327-75-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 抗菌膏
• 英文名称: glutamine-phenylalanine
• 英文别名: Gln-Phe；L-Glutaminyl-Phe；Glutaminylphenylalanine；(2S)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]-3-phenylpropanoic acid
• CAS: 92327-75-8
• 化学式: C₁₄H₁₉N₃O₄
• 分子量: 293.323
• InChiKey: VHLZDSUANXBJHW-QWRGUYRKSA-N

物化性质

• 熔点：
  191-193 °C(Solv: water (7732-18-5); acetone (67-64-1))
• 沸点：
  656.9±55.0 °C(Predicted)
• 密度：
  1.291±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  -3.6
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  136
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  p-Methoxy-carbobenzoxy-Glu(NH2)-Phe-OBut 在 三氟乙酸 作用下， 生成 抗菌膏
  参考文献：
  名称：

  Schroeder,E.; Klieger,E., Justus Liebigs Annalen der Chemie, 1964, vol. 673, p. 196 - 207

  摘要：

  DOI：

文献信息

• Identification of Novel<scp>L</scp>-Amino Acid α-Ligases through Hidden Markov Model-Based Profile Analysis
  作者：Akihiro SENOO、Kazuhiko TABATA、Yoshiyuki YONETANI、Makoto YAGASAKI

  DOI：10.1271/bbb.90644

  日期：2010.2.23

  l-Amino acid α-ligase (Lal), catalyzing the formation of α-dipeptides from unprotected l-amino acids in an ATP-dependent manner, is used in cost-effective fermentative production of dipeptides. We searched for novel Lals by in silico screening using Hidden Markov Model-based profile analysis, and identified five novel Lals that showed low similarity and different substrate specificity from known Lals.

  l- 氨基酸 α-连接酶（Lal）以 ATP 依赖性方式催化未受保护的 l- 氨基酸形成 α-二肽，被用于经济高效的二肽发酵生产。我们利用基于隐马尔可夫模型的剖面分析方法，通过硅筛选寻找新型拉尔，结果发现了五种新型拉尔，它们与已知拉尔的相似性较低，底物特异性也不同。
• Compositions to improve tic disorders
  申请人：Ozeki Makoto

  公开号：US20060217321A1

  公开（公告）日：2006-09-28

  Tic disorders can be improved by administering theanine, an amino acid that crosses the blood-brain barrier, or a dipeptide consisting of theanine and a different amino acid. In addition, these compositions can be added to foods and drinks or pharmaceuticals.

  滴状障碍可以通过给予茶氨酸改善，这是一种可以穿过血脑屏障的氨基酸，或者是由茶氨酸和另一种氨基酸组成的二肽。此外，这些组合物可以添加到食品和饮料或药品中。
• Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
  申请人：BIORESEARCH, INC.

  公开号：EP0727149A2

  公开（公告）日：1996-08-21

  Sweetness inhibitors which are substantially tasteless have been found to be bitter taste inhibitors or blockers. Conversely, bitter taste inhibitors which are substantially tasteless have been found to be sweet taste inhibitors or blockers.

  已发现基本上无味的甜味抑制剂是苦味抑制剂或阻断剂。反之，基本无味的苦味抑制剂被发现是甜味抑制剂或阻断剂。
• Ingestible containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
  申请人：BIORESEARCH, INC.

  公开号：EP0728419A2

  公开（公告）日：1996-08-28

  Sweetness inhibitors which are substantially tasteless have been found to be bitter taste inhibitors or blockers. Conversely, bitter taste inhibitors which are substantially tasteless have been found to be sweet taste inhibitors or blockers.

  已发现基本上无味的甜味抑制剂是苦味抑制剂或阻断剂。反之，基本无味的苦味抑制剂被发现是甜味抑制剂或阻断剂。
• Biomarkers for fatty liver disease and methods using the same
  申请人：Metabolon Inc.

  公开号：EP2546649A2

  公开（公告）日：2013-01-16

  The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.

  本发明提供了脂肪肝的各种生物标志物，包括脂肪变性和脂肪性肝炎。本发明还提供了使用这些生物标志物的各种方法，包括诊断脂肪肝的方法、确定脂肪肝易感性的方法、监测脂肪肝进展/恶化的方法、评估治疗脂肪肝组合物疗效的方法、筛选组合物调节脂肪肝生物标志物活性的方法、治疗脂肪肝的方法以及基于脂肪肝生物标志物的其他方法。